[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
March 5, 2014

Deaths and Cardiovascular Events in Men Receiving Testosterone

Author Affiliations
  • 1Robert Hague Centre for Diabetes and Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, England
  • 2Sheffield Hallam University, Sheffield, England
JAMA. 2014;311(9):962-963. doi:10.1001/jama.2014.398

To the Editor We are concerned that the study by Dr Vigen and colleagues1 has serious flaws in both design and interpretation.

First, Vigen et al1 characterized testosterone treatment as filling a single prescription for any testosterone product and “once initiated, a patient was assumed to have continued treatment ….” This is insufficient for a definition of long-term testosterone therapy, especially when 17.6% received only 1 prescription. Moreover, there were no data on whether patients continued to regularly receive treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×